Baxter International (NYSE:BAX) Releases Q4 2024 Earnings Guidance

Baxter International (NYSE:BAX) updated its fourth quarter 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.770-0.810 for the period, compared to the consensus estimate of 0.840. The company issued revenue guidance of -. Baxter International also updated its FY 2024 guidance to 2.900-2.940 EPS.

Baxter International Trading Down 3.9 %

BAX stock opened at $34.64 on Friday. The business has a fifty day moving average price of $37.39 and a 200 day moving average price of $36.12. The company has a debt-to-equity ratio of 1.35, a current ratio of 1.40 and a quick ratio of 0.91. Baxter International has a fifty-two week low of $32.48 and a fifty-two week high of $44.01. The stock has a market capitalization of $17.67 billion, a price-to-earnings ratio of 7.13, a P/E/G ratio of 1.22 and a beta of 0.60.

Baxter International (NYSE:BAX) last announced its earnings results on Friday, November 8th. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $3.85 billion during the quarter, compared to analyst estimates of $3.85 billion. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company posted $0.68 earnings per share. Analysts expect that Baxter International will post 2.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BAX shares. JPMorgan Chase & Co. reduced their target price on shares of Baxter International from $44.00 to $42.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Wells Fargo & Company decreased their price objective on Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 7th. The Goldman Sachs Group boosted their target price on Baxter International from $36.00 to $40.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Morgan Stanley lowered Baxter International from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $39.00 to $30.00 in a research note on Monday, July 15th. Finally, Citigroup lifted their price objective on Baxter International from $38.00 to $40.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $41.20.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.